The concept of nucleic acid-based therapeutics is not a new one. For a long
time it has been thought that molecules similar to those that make up our
genetic structure would make effective therapeutics. It is an idea whose time
has come.
There are six types of nucleic acid-based therapeutics that have been
proposed. Some have made it to market, others are still in development, and some
have been put on the back burner due to technical difficulties. The six
technologies examines in this study are:
- Antisense
- Ribonucleic acid inhibition (RNAi)
- Gene therapy
- Nucleoside analogs
- Ribozymes, and
- Aptamers
This report focuses on the application of nucleic acid-based therapeutics to
the prevention and treatment of various diseases and disorders:
- Cancer
- Rheumatoid arthritis
- Diabetes (Types I and II)
- Cardiovascular disease (hypertesion, Coronary artery disease, and
congestive heart failure)
- Autoimmune diseases (psoriasis, lupus erythematosus, psoriatic arthritis,
and scleroderma)
- Neurological Diseases (peripheral neuropathies, Alzheimers disease,
epilepsy, Parkinsons disease, multiple sclerosis, severe traumatic brain
injury, and spinal cord injury)
- Viral Diseases, and
- Miscellaneous conditions
The report examines the options that these new therapeutics present, the
progress that is being made in these fields, and the motivations for broader
pharmaceutical industry involvement in these markets. The major market effects
of nucleic acid-based therapeutics are seen as having the potential to
significantly impact the seven major world healthcare markets over the next ten
years. The trends selected in conjunction with the growing interest in
preventive medicine alone, and gene vaccines specifically, and the application
to current health priorities present the most informative picture of advances in
this field and the markets that result.
Market analysis for this report considers the various applications of nucleic
acid-based therapeutics rather than the markets for specific products in the
seven major world healthcare markets:
- United States
- Japan
- Germany
- France
- United Kingdom
- Italy, and
- Spain
The analysis presented in this report is based on data from a combination of
company, government, industry, institutional, and private sources. It includes
information from extensive literature reviews, as well as in-depth interviews
and discussions with experts in the field, including medicinal chemists, experts
in genetics and genomics, medical professionals, research scientists, business
development managers, and marketing managers.
View Cart
